Aerpio Pharmaceuticals (NASDAQ: ARPO) is up a whopping 50% this morning. This article delves into why and gives you the key information you need to make informed decisions when it comes to investing in Aerpio Pharmaceuticals stock.
Scroll down to find out everything you need to know about Aerpio Pharmaceuticals stock. We explain what the company is, what it does, and what our ARPO price forecast is.
For those of you who want to buy ARPO shares immediately, our team of analysts have listed the best places to buy and sell Aerpio Pharmaceuticals stock in the UK and elsewhere below.
How & where to buy ARPO stock online
If you want to invest in ARPO shares quickly and easily, sign up to a low-fee stockbroker, deposit funds and purchase shares.
We believe the two options below are the best platforms to buy, sell and trade Aerpio stock today:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is Aerpio Pharmaceuticals?
It is a biopharmaceutical company that is focussed on developing and eventually commercialising compounds to help the treatment of ocular disease and vascular stabilisation.
The company’s lead product is known as Razuprotafib, which is a small molecule inhibitor of what is known as ‘vascular endothelial protein tyrosine phosphatase.’ Yes, that is indeed a mouthful.
The stock has soared following a bullish research report from H.C. Wainwright analyst, Robert Burns, who has upgraded ARPO stock to a ‘buy’ rating and given it a price target of $22, a massive upgrade on its current valuation of c. $2.50.
Should I buy ARPO stock today?
If you believe in Burns’ analysis, and you think Aerpio can change the game with pioneering treatments, buying now ahead of the company’s future commercial success could be a prudent move.
However, there are huge risks with biopharmaceutical companies. Every product must go through rigorous testing before being approved by the regulators, meaning there are many opportunities for things to go wrong.
Whatever you do, make sure you conduct your own research before getting involved.
ARPO price target
Our Aerpio Pharmaceuticals 12-month price target is $20, very similar to that prescribed by Burns.